2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0430
    Coptisine 3486-66-6 98%
    Coptisine is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine is a reversible, uncompetitive IDO inhibitor with a Ki of 5.8 μM and an IC50 of 6.3 μM. Coptisine suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine can be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease.
    Coptisine
  • HY-N1155
    Theviridoside 23407-76-3 99.58%
    Theviridoside is a natural iridoid glucoside found in the leaves of Cerbera odollam, it has cytotoxicity.
    Theviridoside
  • HY-N1483
    Guanfu base A 1394-48-5 98.10%
    Guanfu base A is an antiarrhythmic alkaloid isolated from Aconitum coreanum and is a potent noncompetitive CYP2D6 inhibitor, with a Ki of 1.20 μM in human liver microsomes (HLMs) and a Ki of 0.37 μM for the human recombinant form (rCYP2D6). Guanfu base A is also a potent competitive inhibitor of CYP2D in monkey (Ki of 0.38 μM) and dog (Ki of 2.4 μM) microsomes. Guanfu base A also inhibits HERG channel current.
    Guanfu base A
  • HY-N1922
    Mesaconine 6792-09-2 99.74%
    Mesaconinean, an ingredient from Aconitum carmichaelii Debx., has cardiac effect.
    Mesaconine
  • HY-N1933
    Allocryptopine 485-91-6 99.53%
    Allocryptopine, a derivative of tetrahydropalmatine, is extracted from Macleaya cordata (Thunb.) Pers. Papaveraceae. Allocryptopine has antiarrhythmic effects and potently blocks human ether-a-go-go related gene (hERG) current.
    Allocryptopine
  • HY-N2107
    Physion 8-O-β-D-glucoside 26296-54-8 98.0%
    Physion 8-O-β-D-glucoside, a bioactive component of Fallopia multiflora, can be used for the research of dizziness.
    Physion 8-O-β-D-glucoside
  • HY-N2299
    Morusinol 62949-93-3 99.68%
    Morusinol is a flavonoid isolated from Morus alba root bark. Morusinol has an antiplatelet activity and  significantly inhibits arterial thrombosis in vivo.
    Morusinol
  • HY-N2929
    β-Hydroxypropiovanillone 2196-18-1
    β-Hydroxypropiovanillone, a natural compound, shows significant concentration-dependent inhibitory effects on α-glucosidase with an IC50 of 257.8 μg/mL.
    β-Hydroxypropiovanillone
  • HY-N2960
    Broussonin A 73731-87-0
    Broussonin A is a potent BChE inhibitor, with an IC50 of 4.16 µM. Broussonin A is a diarylpropane natural product that can be isolated from the bark of Broussonetia papyrifera after solid fermentation.
    Broussonin A
  • HY-N3216
    Nagilactone B 19891-51-1 98.0%
    Nagilactone B is a liver X receptor (LXR) agonist.
    Nagilactone B
  • HY-N3228
    Myrianthic acid 89786-84-5 98.0%
    Myrianthic acid is a pentacyclic triterpenoid compound. Myrianthic acid can exist in the root wood of Myrianthus arboreus and the leaves of Campsis grandiflora. Myrianthic acid inhibits adrenaline-induced platelet aggregation, with a IC50 of 46.2 μM for this activity. Myrianthic acid can be used in studies related to thrombosis.
    Myrianthic acid
  • HY-N3298
    Meranzin 23971-42-8 98.0%
    Meranzin is an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS). Meranzin, isolated from leaves of Murraya exotica L., regulates the shared alpha 2-adrenoceptor and involves the AMPA-ERK1/2–BDNF signaling pathway. Meranzin has the potential for the prevention of the comorbidity of atherosclerosis and depression.
    Meranzin
  • HY-N3470
    Isomartynoside 94410-22-7 99.60%
    Isomartynoside is a potent angiotensin converting enzyme (ACE) inhibitor with an IC50 value of 505.9 µM. Isomartynoside is a phenylpropanoid glycoside that can be found in Galeopsis pubescens. IC50: 505.9 µM (ACE)
    Isomartynoside
  • HY-N3806
    Enniatin B 917-13-5 99.86%
    Enniatin B is a Fusarium mycotoxin. Enniatin B inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 113 μM in an enzyme assay using rat liver microsomes. Enniatins B decreases the activation of ERK (p44/p42).
    Enniatin B
  • HY-N4192
    Toringin 1329-10-8 99.62%
    Toringin, a bioflavonoid, is isolated from the bark of Docyniopsis tschonoski. Toringin progressively decreases not only the cis-effect of the expanded CTG repeats but cytotoxicity as well. Exposure to isosakuranetin, Toringin rescues PC12 neuronal cells. Flavonoids are efficacious for ameliorating the RNA gain of function caused by expanded CTG repeats, and have various biological activities and beneficial actions against cancers, coronary heart disease, among other pathologies.
    Toringin
  • HY-N4213
    Anemarrhenasaponin I 163047-21-0 99.48%
    Anemarrhenasaponin I, a traditional Chinese medicine, shows remarkable inhibiting effect on platelet aggregation.
    Anemarrhenasaponin I
  • HY-N4267
    Yangambin 13060-14-5 98.27%
    Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC50 of 29.7 μM and a Ki of 17.1 μM against human UGT1A1, and an IC50 of 56.5 μM and a Ki of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB4-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca2+ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases.
    Yangambin
  • HY-N4305
    Notoginsenoside FP2 1004988-75-3 99.61%
    Notoginsenoside FP2, a dammarane-Type Bisdesmoside isolated from the Fruit Pedicels of Panax notoginseng, has potential to treat cardiovascular disease.
    Notoginsenoside FP2
  • HY-N5006
    Guanfu base G 78969-72-9 99.91%
    Guanfu base G is an antiarrhythmic alkaloid isolated from Aconitum coreanum. Guanfu base G inhibits HERG channel current with an IC50 of 17.9 μM.
    Guanfu base G
  • HY-N5014
    Liensinine perchlorate 2385-63-9 99.67%
    Liensinine perchlorate is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine perchlorate suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine perchlorate activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine perchlorate exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine perchlorate can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke.
    Liensinine perchlorate
Cat. No. Product Name / Synonyms Application Reactivity